{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=36&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Tucson",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 5391,
    "total_pages": 540,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=37&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=35&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:25:42.541Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00032370",
      "title": "Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Vascular surgery with best medical treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Coronary artery bypass grafting (CABG)",
          "type": "PROCEDURE"
        },
        {
          "name": "Percutaneous transluminal coronary angioplasty (PTCA)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 510,
      "start_date": "1997-08",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2015-06-26",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 18,
      "location_summary": "Tucson, Arizona • No. Little Rock, Arkansas • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "No. Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00032370"
    },
    {
      "nct_id": "NCT00853827",
      "title": "Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease (CAD)",
        "Coronary Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2009-03",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-03",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 54,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853827"
    },
    {
      "nct_id": "NCT02487446",
      "title": "Efficacy and Safety Study of QVA149 in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "QVA149",
          "type": "DRUG"
        },
        {
          "name": "Umeclidinium/vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo (umeclidinium/vilanterol)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (QVA149)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 357,
      "start_date": "2015-07-28",
      "completion_date": "2016-09-12",
      "has_results": true,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 58,
      "location_summary": "Andalusia, Alabama • Anniston, Alabama • Jasper, Alabama + 52 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Multiple Locations",
          "state": "Alabama"
        },
        {
          "city": "Multiple Locations",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02487446"
    },
    {
      "nct_id": "NCT03109379",
      "title": "Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Overactive Bladder With Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Trospium-Releasing Intravesical System (TAR-302-5018)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taris Biomedical LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2017-04-04",
      "completion_date": "2019-09-27",
      "has_results": false,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 12,
      "location_summary": "Tucson, Arizona • San Diego, California • Pompano Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Watertown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03109379"
    },
    {
      "nct_id": "NCT01130142",
      "title": "A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "IPI-926 plus gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2010-04",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • San Diego, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130142"
    },
    {
      "nct_id": "NCT04680156",
      "title": "Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adhesive Capsulitis",
        "Frozen Shoulder"
      ],
      "interventions": [
        {
          "name": "Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-12-17",
      "completion_date": "2022-09-12",
      "has_results": false,
      "last_update_posted_date": "2022-12-30",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04680156"
    },
    {
      "nct_id": "NCT01181479",
      "title": "Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "AG200-15 (cycles 1-13)",
          "type": "DRUG"
        },
        {
          "name": "Lessina crossover to AG200-15",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agile Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "17 Years to 40 Years · Female only"
      },
      "enrollment_count": 1504,
      "start_date": "2010-08",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 80,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Green Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181479"
    },
    {
      "nct_id": "NCT07064759",
      "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration (nAMD)"
      ],
      "interventions": [
        {
          "name": "4D-150 IVT (3E10 vg/eye)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "4D Molecular Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2025-07-22",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 60,
      "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07064759"
    },
    {
      "nct_id": "NCT02174003",
      "title": "Whole Body Hyperthermia Registry Study",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Depression",
        "Anxiety",
        "PTSD",
        "Fibromyalgia",
        "Chronic Fatigue Syndrome"
      ],
      "interventions": [
        {
          "name": "High intensity whole-body infrared heating",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-06",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174003"
    },
    {
      "nct_id": "NCT00220779",
      "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2002-12",
      "completion_date": "2005-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-10-31T05:25:42.541Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220779"
    }
  ]
}